Synthetic Heparins as Safe Disease-modifying Drugs for Early-Stage Treatment of AD via Inhibition of Beta-Secretase: Evaluation in a Transgenic Mouse Model

Research Categorization
Researcher and Organization
Principal Investigator
Principal Investigator First Name
Jerry
Principal Investigator Last Name
Turnbull
Awardee Organization
Contact PI Country
Project Detail
FY Overall Cost
$261,235
Funding Organization
Agency/Funding Organization
Funding Organization Country